grant
Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Jan 2026Deadline 30 Apr 2030
NIHUS FederalResearch GrantFY2026(TNF)-α0-11 years oldActive Follow-upAdverse ExperienceAdverse eventAffectAnterior uveitisAnti-Rejection TherapyArthritisBlindnessBlood SerumCachectinCancersCaringChildChild YouthChildhoodChildren (0-21)ChronicChronic Childhood ArthritisClinical PharmacologyClinical TrialsCounselingD2E7 antibodyDataDiminished VisionDisease remissionDoseDrug ExposureDrug KineticsDrug MonitoringDrugsEvidence based practice guidelinesExposure toFailureFamilyFinancial HardshipFlareFrequenciesFundingGoalsHealth Care CostsHealth Care SystemsHealth CostsHu-mABsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosuppressive TherapyIncentivesIncidenceInflammationInjectionsJuvenile Chronic ArthritisJuvenile Chronic PolyarthritisJuvenile Rheumatoid ArthritisLegal BlindnessLow VisionMacrophage-Derived TNFMaintenanceMalignant NeoplasmsMalignant TumorMasksMedicationMonitoring for RecurrenceMonocyte-Derived TNFMorbidityNatureOpportunistic InfectionsPartial SightPatientsPharmaceutical PreparationsPharmacokineticsProspective StudiesQOLQuality of lifeRandomization trialRandomizedRandomized, Controlled TrialsRecommendationRecurrenceRecurrentRecurrent diseaseReduced VisionRegimenRelapseRelapsed DiseaseRelative RisksRemissionReportingRiskSafetySamplingSerious Adverse EventSerumSevere Adverse EventSubnormal VisionTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTechniquesTherapeuticTherapeutic UsesTherapeutic immunosuppressionTreatment FailureTumor Necrosis FactorTumor Necrosis Factor-alphaUveitisVisitVisual AcuityVisual impairmentactive followupadalimumabadverse event riskarmarthriticartificial immunosuppressionburden on familiesburden to familieschild patientsclinical centerclinical investigationcostdetermine efficacydisease controldisorder controldrug/agenteconomic hardshipeconomic strainefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyevidence baseevidence based guidelinesevidence based recommendationsexamine efficacyexperiencefamilial burdenfamily burdenfinancial adversityfinancial burdenfinancial distressfinancial insecurityfinancial instabilityfinancial strainfinancial stressfinancial worryfollow upfollow-upfollowed upfollowuphumAbshuman mAbshuman monoclonal antibodieshuman monoclonalsimmune suppressionimmune suppressive activityimmune suppressive functionimmunosuppression therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseindividualized managementindividualized patient managementinterestjuvenile arthritisjuvenile idiopathic arthritiskidslegally blindmalignancyneoplasm/cancerpatient populationpediatricpediatric patientspersonalization of treatmentpersonalized clinical managementpersonalized disease managementpersonalized managementpersonalized medicinepersonalized therapypersonalized treatmentpharmacokinetic modelprecision managementprecision medicineprecision-based medicineprospective research studyprospective surveyrandomisationrandomizationrandomized control trialrandomized trialrandomly assignedresponseresponse to therapyresponse to treatmentsecondary outcomeserious adverse experienceserious adverse reactionstandard of caretherapeutic responsetherapy failuretherapy optimizationtherapy responsetreatment optimizationtreatment responsetreatment responsivenesstreatment trialvision impairmentvision lossvisual lossvisually impairedyoungster
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic condition in children, and 12-38% of patients
with JIA develop chronic asymptomatic anterior uveitis, typically within 4 to 7 years of arthritis onset. JIA-
associated uveitis can cause significant morbidity, with as many as 1/3 of all patients developing…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click